Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CART123 Cells · 1 trial · 2 indications
Type, frequency, severity, and attribution of AEs/SAEs, including the incidence and severity of IEC-associated adverse events.
| Arm | Type | Description |
|---|---|---|
| Arm A: DL1 | EXPERIMENTAL | * LD Chemo: Day -6 to Day -4 (±1d) * Ruxolitinib: Daily beginning on Day -6 (±1d) through D14 post CART123 infusion. * CART123 Cells: Single infusion on Day 0 |
| Arm A: DL-1 | EXPERIMENTAL | * LD Chemo: Day -6 to Day -4 (±1d) * Ruxolitinib: Daily beginning on Day -6 (±1d) through D14 post CART123 infusion. * CART123 Cells: Single infusion on Day 0 |
| Arm B: DL-1 | EXPERIMENTAL | * LD Chemo: Day -6 (-1d) to Day -2 (-1d) * Venetoclax: Day -6 (-1d) through Day +7 - Day +14 post-CART123 infusion * Ruxolitinib: Daily beginning on Day -1 through Day +7 post CART123 infusion. * CART123 Cells: Single infusion on Day 0 |
| Name | Type | Description |
|---|---|---|
| CART123 Cells | BIOLOGICAL | 1.3x10\^8 CART123 cells |
| Ruxolitinib 10 MG | DRUG | Twice Daily |
| Ruxolitinib 5 MG | DRUG | Twice Daily |
Inclusion Criteria: * 1\. Signed informed consent form 2. Male or female age ≥ 18 years. 3. Patients with active acute myeloid leukemia (AML) with no available curative treatment options using currently available therapies. This is specifically defined as one of the following: 1. AML that has no...
CART123 Cells is an investigational cell therapy being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML). It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
CART123 Cells is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS.
CART123 Cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by the FDA or other regulatory agencies and is still undergoing clinical trials to evaluate its safety and efficacy.
CART123 Cells is being studied in a Phase 1 clinical trial with the identifier NCT06768476. This trial, titled "CART123 + Ruxolitinib in Relapsed/Refractory AML," is active but not recruiting participants and is being conducted in the United States.
CART123 Cells is a distinct investigational cell therapy product. No alternative names for this drug have been reported in the available clinical trial information.